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Radiation therapy alone versus radiation
therapy plus radiofrequency ablation/
vertebral augmentation for spine
metastasis: study protocol for a randomized
controlled trial
Rupesh Kotecha1,2* , Brian J. Schiro3, Justin Sporrer4, Muni Rubens5, Haley R. Appel1, Kathleen S. Calienes5,
Belinda Boulanger5, Marietsy V. Pujol5, Deborah T. Suarez5, Ashley Pena5, Alex Kudryashev5 and Minesh P. Mehta1,2

Abstract
Background: Spine metastasis is a common occurrence in cancer patients and results in pain, neurologic deficits,
decline in performance status, disability, inferior quality of life (QOL), and reduction in ability to receive cancerdirected therapies. Conventional external beam radiation therapy (EBRT) is associated with modest rates of pain
relief, high rates of disease recurrence, low response rates for those with radioresistant histologies, and limited
improvement in neurologic deficits. The addition of radiofrequency ablation/percutaneous vertebral augmentation
(RFA/PVA) to index sites together with EBRT may improve pain response rates and corresponding quality of life.
Methods/design: This is a single-center, prospective, randomized, controlled trial in patients with spine metastasis
from T5-L5, stratified according to tumor type (radioresistant vs. radiosensitive) in which patients in each stratum
will be randomized in a 2:1 ratio to either RFA/PVA and EBRT or EBRT alone. All patients will be treated with EBRT
to a dose of 20–30 Gy in 5–10 fractions. The target parameters will be measured and recorded at the baseline clinic
visit, and daily at home with collection of weekly measurements at 1, 2, and 3 weeks after treatment, and at 3, 6, 12,
and 24 months following treatment with imaging and QOL assessments.
Discussion: The primary objective of this randomized trial is to determine whether RFA/PVA in addition to EBRT
improves pain control compared to palliative EBRT alone for patients with spine metastasis, defined as complete or
partial pain relief (measured using the Numerical Rating Pain Scale [NRPS]) at 3 months. Secondary objectives
include determining whether combined modality treatment improves the rapidity of pain response, duration of
pain response, patient reported pain impact, health utility, and overall QOL.
(Continued on next page)
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Background
Metastasis to the spine is a common complication of
cancer, with approximately 40% of patients developing
clinically significant disease. In autopsy series, up to 90%
of patients with metastatic cancer have been identified
as having micrometastatic spine disease [1]. Bone pain
from spine metastasis is associated with increasing disability rates in these patients [2]. Furthermore, unlike
other bone metastasis, spine metastasis results in vertebral body instability, sensory and motor neurologic deficits, and spinal cord or cauda equina compression,
which can compromise a patient’s functional status and
ability to receive other cancer-directed therapies. The
standard treatment for patients with spine metastasis is
fractionated external beam radiotherapy (EBRT), typically delivered in 1–10 fractions. The Radiation Therapy
Oncology Group (RTOG) 97-14 trial randomized patients with bone metastasis (including spine disease) to
8 Gy in 1 fraction or 30 Gy in 10 fractions and demonstrated comparable outcomes between both arms, leading to the utilization of both schedules in clinical
practice [3]. However, the duration and rate of pain control for the subset of patients with spine metastasis in
both arms was quite modest, with only 61% of patients
reporting complete or partial pain relief 1 month posttreatment. An alternative approach for patients with localized spine metastasis is spine stereotactic radiosurgery
(SRS). Although retrospective series with this technique
are promising, they remain unvalidated in the absence of
prospective randomized data [4]. In addition, it is unclear how many patients are eligible for this highly precise treatment given that more than 50% of patients with
spine metastasis have involvement across multiple levels
and up to 38% have involvement of multiple, noncontiguous segments [5]. Further, there is a defined rate
of late vertebral collapse consequential to SRS, which
can worsen clinical symptoms.
Radiofrequency ablation, with or without percutaneous
vertebral augmentation (RFA/PVA), has been used to
treat pathologic fractures associated with spine metastasis with high rates of initial pain response [6]. Using this
technique, disease in the central portion of the vertebral
body, or that approaching the posterior elements, is first
treated with lethal thermal radiofrequency (RF) energy,
and the remaining bone is reinforced with cement to
provide stability. Retrospective series have demonstrated
significant early pain response and reduction in narcotic

use as early as 1 week post-treatment [7]. Investigation
into the benefits of a multi-modality approach is warranted, as RFA offers rapid pain relief but has limited
oncologic effect by not addressing the entirety of the
vertebral metastatic disease, especially in lesions in paraspinal locations and with disease in posterior elements.
A small, non-randomized feasibility study of RFA and
EBRT forms the basis of the combined modality approach investigated in this trial. In this study of 15 patients with bone metastasis and a pre-treatment pain
score of at least 5 treated with RFA and EBRT (20 Gy in
5 fractions) matched to patients treated with EBRT
alone, higher rates of complete pain response (53.3 vs.
16.6%, p = 0.027) and overall pain response (93.3 vs.
59.9%, p = 0.048) were observed [8]. This study was limited by the RF technology available at the time, lack of
PVA in at-risk patients, as well as small sample size;
therefore, further randomized prospective evidence is
needed to characterize the benefits of modern combined
modality techniques.
The primary objective of this randomized, controlled
trial is to determine whether RFA/PVA in addition to
EBRT improves pain control compared to EBRT alone
for patients with spine metastasis. Secondary objectives
include determining whether combined modality treatment improves the rapidity of pain response, duration of
pain response, patient reported pain impact, health utility, and overall quality of life (QOL).

Methods/design/interventions
This study is a single-center, prospective, randomized,
controlled trial of patients with spine metastasis with
two arms. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT)
guidelines (see Additional file 1). Eligible patients will
have spine metastasis from T5 to L5 (within the treatment limits of RFA/PVA). There is no limit to the maximal involvement of contiguous vertebral bodies with
metastatic disease, as long as an index lesion of pain can
be determined and fewer than two sites would undergo
RFA/PVA in total. All patients will undergo an MRI of
the involved spine within 6 weeks prior to registration to
determine the extent of spine involvement and must
score their index lesion-associated pain as at least 5
using the Numerical Rating Pain Scale (NRPS). In the
control arm, patients will receive conventional palliative
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EBRT to any of the following dose and fractionation
schedules per the discretion of the treating physician: 20
Gy in 5 fractions, 24 Gy in 6 fractions, and 30 Gy in 10
fractions. Single fraction radiotherapy is not allowed in
this study since this has been associated with higher incidence of re-treatment [9] and that fractionated regimens are more traditionally used in patients who have
undergone percutaneous or surgical interventions. Patients randomized to the experimental arm will undergo
RFA/PVA followed by EBRT using the same dose/fractionation schedules. All supportive therapy for optimal
medical care will be given during the study period at the
discretion of the attending physician(s) within the parameters of the protocol and documented as concomitant medications. Chemotherapy is not permitted within
24 h prior to or concurrently with EBRT. In addition,
the patient can receive chemotherapy no earlier than 24
h after EBRT. If a deviation from the protocol occurs,
the PI will complete and electronically submit the
“Protocol Deviation Form.”
The target parameters will be measured and recorded at
the baseline clinic visit (on the day of treatment) and daily
at home with collection of weekly measurements at 1, 2,
and 3 weeks after treatment, and at 3, 6, 12, and 24
months following treatment with imaging and QOL assessments (see Table 1). There will be no special criteria
for discontinuing or modifying allocated interventions
given that both are standard of care interventions (Fig. 1).
Recruitment and randomization

All patients will be enrolled in this trial at the treating
institution, Baptist Health South Florida, Inc. Patients
will be provided with information about this study by

the medical personnel and research staff in the radiation
oncology department when evaluated in consultation for
palliative EBRT to spine metastasis. The medical charts
of interested patients will be reviewed by the research
staff to ensure each patient meets eligibility criteria. Radiation oncologists will discuss patient eligibility for the
trial with the interventional radiology and neurosurgical
teams and review relevant imaging to determine the sites
for RFA/PVA. Patients will also meet with the procedural team, either neurosurgery or interventional radiology, to discuss the logistics, risks, and benefits of the
procedure. Given this patient population with metastatic
disease and the follow-up intervals occurring at routine
time points and coordinated with imaging studies, it is
expected that the combination of these will help boost
participant retention and completion of follow-up
events. All patients who enroll onto this clinical trial will
sign an informed consent document which outlines the
research study in detail. The principal investigator or
sub-investigators will describe the study to the patient
and obtain written informed consent.
Patients enrolled onto this trial will be stratified according to the tumor type (radioresistant [soft tissue sarcoma, melanoma, and renal cell carcinoma] versus other
non-hematologic tumor histologies). The treatment allocation scheme will be used for randomization to balances these patient factors [10]. Within each stratum,
patients will be randomized in a 2:1 ratio to either RFA/
PVA and EBRT or EBRT alone. This unequal
randomization was chosen given the well-known and
documented pain response rates to EBRT, accommodates increased demand for combined modality treatment, allows for a larger sample in the combined

Table 1 Study parameter table
Assessments

Pre-treatment

History/physical

Within 2 weeks
prior to
registration

X

Performance status

Baseline

X

Neurological exam

Within 1 week
prior to
registration

X

Imaging of the spine (CT scan/bone
scan is allowed, MRI preferred)

Within 6 weeks
prior to
registration

X

Numerical rating pain scale and
documentation of patient’s pain
medicationa

Within 1 week
prior to
registration

FACT-G (FA), BPI (QL), EQ-5D (HP)

Baseline

Adverse event evaluation
a

NRPS at 3 months is required for analysis of the primary endpoint

1 month from randomization

(On the day of treatment)
(At home: Daily with cumulative weekly
measurements at 1, 2, and 3 weeks; bring to clinic at
1 month)
In clinic at 1 month

Follow-up: At 3, 6, 12, 24
months from randomization

X

At 3, 6, 12, and 24 months
from randomization
X

X
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Fig. 1 Flowchart of the clinical trial

modality group to evaluate for potential adverse events,
and follows the paradigm established by RTOG 0631.
The randomization will be performed by a statistician
using stratified permuted block randomization. Allocation concealment technique will be used to prevent selection bias and will be performed on an offsite
computer. The recruitment phase will conclude when 52
patients have enrolled in the trial (35 in the RFA/PVA
and EBRT arm and 17 in the EBRT alone arm), and it is
expected that accrual should be completed over a course
of 18 months.

Inclusion criteria

The target population for this trial includes patients with
metastatic disease to the spine, between T5 and L5, as
detected by any imaging study. There is no limit on the
maximal involvement of contiguous vertebral bodies of
disease as long as the index lesion(s) can be treated with
RFA/PVA and fewer than 2 sites need to undergo treatment in total. Patients must have a Zubrod performance
status of 0–3 and can have other sites of visceral or osseous metastatic disease. Patients with epidural extension
of disease are eligible for this study provided that there
is ≥ 3-mm distance between the spinal cord and the edge
of the metastasis. Key ineligibility criteria include metastatic disease from radiosensitive histologies (myeloma,
lymphoma, small-cell lung cancer, or germ-cell tumors),
those with frank spinal cord compression, or those with
rapid neurologic decline or bony retropulsion necessitating urgent neurosurgical intervention.

Assessment of the primary and secondary endpoints

The primary endpoint for this trial is pain response, defined as complete or partial pain relief, as measured
using the NRPS at 3 months (post-treatment pain score
of 0 or at least 3 NRPS points). The NRPS is a widely
utilized assessment of pain intensity in oncologic clinics
and has demonstrated reliability in studies of small sample sizes and in settings where repeated measurements
are obtained to monitor changes in pain intensity over
time [11]. Using this scale, complete pain relief is defined as a pain score of 0 with no increase in narcotic
pain medication, and partial pain relief is defined as a reduction in numerical pain score of at least 2 points at
the index site with no increase in pain medication.
Secondary pain response endpoints include the rapidity of pain response, as defined as the time from study
entry to complete or partial pain relief, and duration of
pain response, as defined as the time from complete or
partial pain relief to pain worsening (≥ 3 NRPS points).
To assess these outcomes, patients will complete the
NRPS for each treatment site at the baseline clinic visit
(on the day of treatment) and daily at home with weekly
measurements at 1, 2, and 3 weeks after randomization
in addition to a diary of their pain medication use and
any side effects they experience related to the treatment.
One month after treatment, patients will complete the
NRPS, and at the clinic visit, the research team will consolidate the patients’ pain level scores, pain medications,
and document adverse events. Imaging of the treated
spine will be obtained at baseline and at 3, 6, 12, and 24
months after randomization to assess the response to
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treatment as well as subacute or long-term change of
the vertebral bone.
The study hypothesis is that given the potential benefit
of combined modality treatment in providing rapid and
durable pain relief, QOL will improve after RFA/PVA and
EBRT. Therefore, a number of QOL outcomes will also be
prospectively collected in this study, including QOL, as
measured by the Functional Assessment of Cancer Therapy (FACT-G) [12]; patient perception of pain, as measured by the Brief Pain Inventory (BPI) [13]; and health
utilities, as measured by the EuroQol (EQ-5D) [14] at 3, 6,
12, and 24 months post-study randomization.
Radiotherapy

All patients enrolled onto this clinical trial will receive
EBRT (Fig. 1). CT simulation will be performed after
randomization in a stable and comfortable position to
allow for reproducibility from simulation to treatment.
A variety of immobilization systems may be utilized, depending on the location and extent of spine disease to
be treated. Image co-registration of the diagnostic MRI
to the simulation CT can be performed if there is concern for soft tissue tumor component or epidural extension of disease. The gross tumor volume (GTV) contour
represents the index spine lesion(s) and should include
the entirety of the vertebral body, canal, pedicles, transverse processes, and spinous process as well as any paraspinal or epidural disease, if present. The clinical target
volume (CTV) will include the involved index spine lesion(s) as well at least one spine level superior and inferior to the index lesion(s). Depending on site, treatment
technique, and immobilization, the planning target volume (PTV) will consist of a 3–5-mm circumferential expansion only. Patients may be treated with 3D-CRT or
IMRT at the discretion of the treating physician. The
following fractionation schedules will be deemed equivalent and used in this study: 20 Gy in 5 fractions, 24 Gy in
6 fractions, and 30 Gy in 10 fractions [15].
Radiofrequency ablation and vertebral augmentation

Patients randomized to RFA/PVA will undergo the procedure under moderate sedation in the angiographic
suite or with monitored anesthesia care in the operating
room. RFA/PVA will be performed with the patient in
the prone position. Unipedicular or bipedicular approaches will be used depending on the anatomy and location of the metastatic spine disease. During the
procedure, 10-G trocar needles will be placed via a
transpedicular or parapedicular approach, and once positioned, RFA will be performed. All RFA procedures
will be performed with the OsteoCool™ RF Ablation System (Medtronic Inc.) through the trocar needles. This
consists of a coaxial, bipolar technology which delivers
RF energy to the site of spine disease. The internally
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cooled ablation probes control the temperature which
helps to keep RF heating within the desired treatment area
and reduces the potential thermal damage to the adjacent
tissue. Two probes may be used simultaneously, depending on the anatomy, to achieve larger ablation zones, and
time adjustments can be made to control the size of the
ablation zone. Once the RFA procedure has completed,
PVA will be performed, as necessary, using 11-G needles
advanced through the trocars and into the anterior 1/3 of
the vertebral body. Kyphon high viscosity bone cement
will be administered until the cement adequately fills the
vertebral body/ablation zone or until the cement leakage
precludes additional filling of the vertebral body. Kyphoplasty balloon augmentation will be performed at the discretion of the operator prior to cement administration.
Once the entire procedure is completed, the patient will
be transferred to the recovery area for a minimum of 3 h
to allow the bone cement to solidify. Patients will be discharged the same or next day.
Data management

MCI provides an in-house Clinical Scientific Review
Committee (CSRC). The CSRC is responsible for reviewing all diagnostic, therapeutic, and non-therapeutic cancer research studies conducted at MCI. The MCI Data
Safety and Monitoring Committee (DSMC) is responsible for assessing study progress, the reporting of adverse events and unanticipated problems, and the
accuracy and integrity of the research data and protocol
compliance. The DSMC is composed of representative
physician experts and meets requirements as set forth
from the NIH. This study will be reviewed by the MCI
DSMC, independent from the investigator and study
funder, every 3 months as per the assigned risk score.
Both committees collaborate to ensure that the clinical
trial is being conducted in regulatory compliance.
MCI studies are each assigned one or more Clinical
Research Coordinators (CRCs) and Research Assistants
(RAs) based on therapeutic area. CRCs are responsible
to assist the PIs in the scheduling of patients and collection of study-related data from patients (surveys/questionnaires). RAs are responsible for data entry into
MCI’s electronic data capture (EDC) system. MCI Data
Management Coordinators (DMCs) are responsible for
creating electronic Case Report Forms (eCRFs) for research study. RAs enter data into these eCRFs, which is
then validated. At interim and/or final analysis, MCI
DMCs export the study dataset and provide it to the PI
and MCI Biostatistician for data analysis.
Data will be entered into MCI’s electronic data capture
(EDC) system (21 CFR Part 11 compliant), which is a secured system used to collect and manage data for clinical research studies. This system is currently in use for
MCI institutional studies. Patients will be identified by
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initials only (first, middle, last); if there is no middle initial, a hyphen will be used (first-last). Last names with
apostrophes will be identified by the first letter of the
last name. Data collected during the course of research
will be kept strictly confidential and only accessed by
members of the study team. Other staff employed by
BHSF (sponsor) may have access to study participant
data as part of their routine job duties. All staff are governed by the BHSF confidentiality policy and HIPAA
guidelines.
Statistical analysis

Based on the reported incidence of complete or partial pain response from the results of the feasibility
matched cohort study of RFA/PVA and EBRT [8],
with a two-sided α = 0.05 and β = 0.20 and a study design of 2:1 randomization scheme (RT plus PVA/RFA:
RT), the study will be adequately powered with 52
patients (35 in the RT plus PVA/RFA arm and 17 in
the RT arm). Assuming a 5% ineligibility rate, a death
rate of 15%, and a patient non-compliance rate of
15%, the total sample size required would be 80
patients. No interim analyses with treatment efficacy
results are planned. The primary endpoint is complete
or partial pain response at 3 months after
randomization, and all eligible, randomized patients
will be included in the analysis regardless of treatment compliance (intent-to-treat analysis). Descriptive
statistics of the actual change scores, mean change
scores, and standard deviations will also be reported.
For analysis of the secondary pain response endpoints
(rapidity of pain response and duration of pain response), the median time to each outcome variable
will be estimated using the Kaplan-Meier approach,
the stratified log-rank test will be used to test for statistically significant differences with an α = 0.025, and
the Cox proportional hazards regression model will
be used to determine hazard ratios and 95% confidence intervals for the treatment differences. Moreover, unadjusted ratios and adjusted ratios for
radiosensitive vs. radioresistant histology will be computed. The incidence of adverse events will be reported according to CTCAE v5.0, and differences in
the rates at 3 months between the two treatment
arms will be tested using the two-sided chi-square
test at the 0.05 significance level. To analyze differences in QOL, global pain, and health utility, changes
in FACT-G, BPI, and EQ-5D will be described with
longitudinal data analysis. The mean differences will
be compared across the treatment arms using the two
sample t test at the 0.025 significance level. The relationship between treatment response and QOL will
also be analyzed using the two sample t test at the
0.025 significance level.
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Ethics issues, information, and safety

The study protocol and patient informed consent documents were submitted to the Institutional Review Board
at Baptist Health South Florida and approval was
granted in 3/2020 (#1544454-2). As both treatment arms
in this trial are currently approved in the routine care of
patients with spine metastasis, insurance approval for
the study treatment will be obtained from patients’ insurance providers. Interim reports with descriptive statistics will be prepared twice a year until the final study
results are available. In general, the interim reports will
contain information about the accrual rate with a projected completion date for the accrual phase, data quality, compliance rate of the treatment, and frequencies
and severity of the adverse events. Unexpected adverse
events (AEs) will be graded by the treating physician,
assigned an attribution, and then reported to the principal investigator and study sponsor depending on grade
and attribution using CTCAE v5.0. The interim reports
will not contain treatment efficacy results with respect
to the primary or secondary endpoints.

Discussion
Spine metastasis is a common occurrence in patients
with metastatic disease and results in pain, neurologic
deficits, decline in performance status, disability, inferior quality of life, and reduction in ability to receive cancer-directed therapies. To date, there have
been more than 20 randomized controlled trials, 32
prospective non-randomized studies, and 4 metaanalyses/pooled analyses regarding the role of palliative EBRT for patients with bone metastasis [15]. Despite this wealth of research, there are clear limitations
to conventional EBRT, including modest rates of pain
relief [3], high rates of disease recurrence [16], very
low response rates for patients with various histologies (including sarcoma, melanoma, gastrointestinal,
non-small cell lung cancer, and renal cell carcinoma)
[17], and limited benefit in neurologic deficit improvement [17]. Therefore, the aim of this randomized clinical trial is to assess the efficacy of combined
modality therapy with RFA/PVA together with EBRT
compared to EBRT alone. We hypothesize that the
addition of RFA/PVA may result in a robust and clinically meaningful improvement in the proportion of
patients with spine metastasis experiencing pain relief
at 3 months. Temporal analyses of the rapidity of pain
response and duration of benefit will also provide important comparative outcomes. Finally, inclusion of
key parameters of pain impact, health utility, and
quality of life will lead to a better understanding of
the relationship between metastatic disease of the
spine and important patient-centric outcomes.
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Trial status
Version 3.0 of the protocol, revised last on April 7, 2020,
received IRB approval on April 19, 2020. The study is
currently open to patient accrual as of May 2020, and
the accrual period is expected to last 18 months. Protocol amendments, if needed, will be reviewed by the study
sponsor and submitted the IRB.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-04895-x.
Additional file 1. SPIRIT 2013 Statement: Defined Standard Protocol
Items.
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